Utah Medical Products (UTMD) Peer Comparison
$69.16
$-1.94
(-2.73%)
As on 08-Sep-2026 16:00EDT
Market cap
$226 Mln
Revenue (TTM)
$36 Mln
P/E Ratio
21.7
P/B Ratio
1.8
Div. Yield
1.8 %
Edit
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
226 | 12,650 | 10,638 | 9,762 | 9,459 |
Revenue ($ Mln) |
36 | 1,505 | 613 | 2,589 | 785 |
Net Profit ($ Mln) |
10.49 | 160.59 | -188.05 | 222.40 | 41.54 |
Net Margin (%) |
29.04 | 10.67 | -30.68 | 8.59 | 5.29 |
RoE (%) |
8.69 | 10.86 | -28.10 | 3.04 | 1.97 |
Price to Earnings |
21.68 | 79.29 | -- | 44.47 | 232.78 |
Price-To-Book |
1.84 | 8.31 | 15.27 | 1.36 | 4.62 |
Income Statement ($ Mln)
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
36.11 | 1,504.87 | 612.84 | 2,589.30 | 785.10 |
|
Cost of Revenue
|
16.29 | 483.98 | 127.96 | 1,245.50 | 384.30 |
|
Gross Profit
|
19.88 | 942.44 | 393.22 | 1,343.60 | 347.62 |
|
Operating Expenses
|
9.54 | 833.56 | 565.37 | 1,108.90 | 335.50 |
|
Operating Profit (EBIT)
|
10.28 | 187.34 | -80.49 | 235.00 | 65.30 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
12.88 | 203.83 | -192.83 | 350.40 | 52.15 |
|
Provision for Tax
|
2.40 | 43.24 | -4.79 | 128.00 | 10.61 |
|
Profit after Tax (Net Income)
|
10.49 | 160.59 | -188.05 | 222.40 | 41.54 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 93.19 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
122.03 | 1,530.77 | 682.49 | 7,173.90 | 2,112.03 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
0.47 | 210.18 | 135.71 | 2,116.80 | 705.49 |
|
Current Liabilities
|
2.07 | 233.78 | 102.33 | 961.30 | 132.66 |
|
Total Liabilities
|
122.54 | 1,826.52 | 893.49 | 10,576.50 | 2,949.70 |
Assets ($ Mln)
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
23.93 | 630.60 | 404.74 | 7,231.50 | 1,749.63 |
|
Current Assets
|
100.64 | 1,344.12 | 515.78 | 3,020.50 | 1,200.55 |
|
Total Assets
|
122.54 | 1,826.52 | 893.49 | 10,576.50 | 2,949.70 |
|
Total Debt*
|
0.20 | 212.71 | 102.84 | 1,203.70 | 690.94 |
|
Net Current Assets
|
98.57 | 1,110.35 | 413.45 | 2,059.20 | 1,067.90 |
Cashflow ($ Mln)
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
14.69 | 238.66 | -46.34 | 532.20 | 117.42 |
|
Cash Flow from Investing Activities
|
-0.37 | -404.59 | -77.61 | -189.70 | -298.47 |
|
Cash from Financing Activities
|
-12.34 | 26.53 | 11.89 | -283.20 | -15.21 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
9.51 | 11.76 | -22.53 | 8.98 | 1.79 |
|
ROE (%)
|
8.69 | 10.86 | -28.10 | 3.04 | 1.97 |
|
ROA (%)
|
8.40 | 7.95 | -18.00 | 2.02 | 1.36 |
|
EBIT Margin (%)
|
33.94 | 13.63 | -30.58 | -5.99 | 9.87 |
|
Net Margin (%)
|
29.04 | 10.67 | -30.68 | 8.59 | 5.29 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-7.00 | 17.55 | 41.55 | 1.37 | 16.49 |
|
EBIT Growth (%)
|
-16.92 | 17.49 | -116.42 | -131.06 | 920.91 |
|
Net Profit Growth (%)
|
-16.47 | 8.72 | -102.66 | -30.32 | 400.42 |
|
EPS Growth (%)
|
-12.17 | 8.12 | -96.88 | -29.66 | 394.30 |
|
Book Value Growth (%)
|
5.86 | 17.33 | -12.65 | 2.19 | 2.16 |
Valuation Ratios
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
15.86 | 68.93 | -34.59 | -- | 189.42 |
|
Price / Book Value
|
1.50 | 8.58 | 9.90 | -- | 4.40 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
5.48 | 53.25 | -43.50 | -- | 55.90 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.11 | 0.26 |
|
Short term debt to equity ratio
|
0.00 | 0.01 | 0.00 | 0.06 | 0.01 |
|
Current Ratio
|
48.62 | 5.75 | 5.04 | 3.14 | 9.05 |
|
Quick Ratio
|
44.27 | 3.86 | 4.46 | 2.33 | 7.64 |
|
Interest Coverage
|
-- | 157.91 | -38.31 | 8.18 | 1.92 |
Operating Efficiency Ratios
| Utah Medical Products (UTMD) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
9.87 | 12.65 | 22.67 | 17.06 | 20.09 |
|
Asset Turnover
|
0.29 | 0.74 | 0.59 | 0.24 | 0.26 |
|
Receivable days
|
36.11 | 46.54 | 60.95 | 65.39 | 72.41 |
|
Inventory Days
|
164.03 | 331.92 | 193.84 | 221.09 | 146.53 |
|
Payable days
|
14.24 | 26.16 | 60.19 | 37.02 | 29.05 |
|
Cash Conversion Cycle
|
185.90 | 352.30 | 194.60 | 249.46 | 189.88 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
